Literature DB >> 10714618

Management of nonresponse and intolerance: switching strategies.

M Fava1.   

Abstract

Approximately 29% to 46% of depressed patients show only partial or no response to treatment with antidepressants, with intolerance a frequent cause of treatment failure or discontinuation. Clinicians frequently switch to other antidepressants patients who have failed to tolerate or to respond to antidepressant treatment. The switching strategy involves substitution of another agent for the agent that has either caused intolerable side effects or has failed to induce a response. Fredman and colleagues have recently surveyed 402 psychiatrists from various parts of the country and asked them what steps they would take for patients who fail to respond to 8 weeks or more of an adequate dose of a selective serotonin reuptake inhibitor (SSRI). Interestingly, switching to a non-SSRI agent was the most popular choice indicated by psychiatrists (44% of respondents), with dual-acting agents and bupropion being the next most commonly chosen agents. Even though there are no controlled trials of switching strategies in the literature to date, clinicians often choose this course of action. This article will review some of the currently available studies on switching strategies.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10714618

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  9 in total

1.  The role of monoamine oxidase inhibitors in current psychiatric practice.

Authors:  Jess G Fiedorowicz; Karen L Swartz
Journal:  J Psychiatr Pract       Date:  2004-07       Impact factor: 1.325

2.  Cariprazine Augmentation to Antidepressant Therapy in Major Depressive Disorder: Results of a Randomized, Double-Blind, Placebo-Controlled Trial.

Authors:  Willie R Earley; Hua Guo; György Németh; Judit Harsányi; Michael E Thase
Journal:  Psychopharmacol Bull       Date:  2018-06-20

3.  A double-blind pilot dosing study of low field magnetic stimulation (LFMS) for treatment-resistant depression (TRD).

Authors:  Marc J Dubin; Irena P Ilieva; Zhi-De Deng; Jeena Thomas; Ashly Cochran; Kamilla Kravets; Benjamin D Brody; Paul J Christos; James H Kocsis; Conor Liston; Faith M Gunning
Journal:  J Affect Disord       Date:  2019-02-14       Impact factor: 4.839

4.  Loudness dependence of the auditory evoked potential and response to antidepressants in Chinese patients with major depression.

Authors:  Tien-Wen Lee; Younger W Y Yu; Tai-Jui Chen; Shih-Jen Tsai
Journal:  J Psychiatry Neurosci       Date:  2005-05       Impact factor: 6.186

5.  The Indiana Cancer Pain and Depression (INCPAD) trial Design of a telecare management intervention for cancer-related symptoms and baseline characteristics of study participants.

Authors:  Kurt Kroenke; Dale Theobald; Kelli Norton; Rebecca Sanders; Susan Schlundt; Stephanie McCalley; Pamela Harvey; Karen Iseminger; Gwendolyn Morrison; Janet S Carpenter; Dawana Stubbs; Rakeva Jacks; Caroline Carney-Doebbeling; Jingwei Wu; Wanzhu Tu
Journal:  Gen Hosp Psychiatry       Date:  2009-04-05       Impact factor: 3.238

6.  Caffeine protects against stress-induced murine depression through activation of PPARγC1α-mediated restoration of the kynurenine pathway in the skeletal muscle.

Authors:  Chongye Fang; Shuhei Hayashi; Xiaocui Du; Xianbin Cai; Bin Deng; Hongmei Zheng; Satoshi Ishido; Hiroko Tsutsui; Jun Sheng
Journal:  Sci Rep       Date:  2021-03-31       Impact factor: 4.379

7.  CXCL1 Regulated by miR-302e Is Involved in Cell Viability and Motility of Colorectal Cancer via Inhibiting JAK-STAT Signaling Pathway.

Authors:  Biyin Chen; Li Song; Xiuzhen Nie; Fangfeng Lin; Zongyang Yu; Wencui Kong; Xiaoyan Qi; Wenwu Wang
Journal:  Front Oncol       Date:  2021-05-17       Impact factor: 6.244

8.  Efficacy of a systematic depression management program in high utilizers of primary care: a randomized trial.

Authors:  Anne Berghöfer; Astrid Hartwich; Michael Bauer; Jürgen Unützer; Stefan N Willich; Andrea Pfennig
Journal:  BMC Health Serv Res       Date:  2012-09-03       Impact factor: 2.655

9.  Efficacy of adjunctive low-dose cariprazine in major depressive disorder: a randomized, double-blind, placebo-controlled trial.

Authors:  Maurizio Fava; Suresh Durgam; Willie Earley; Kaifeng Lu; Robert Hayes; István Laszlovszky; György Németh
Journal:  Int Clin Psychopharmacol       Date:  2018-11       Impact factor: 1.659

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.